Merrill maintains Amgen at neutral

Amgen Inc. was kept at its neutral rating by Merrill Lynch analyst Eric Ende after the company reported in-line revenues and operating expenses as well as better earnings per share. The company raised earnings per share guidance by $0.10 to reflect higher gross margins, due in part to strong Aranesp sales. In addition, the District Court in Massachusetts confirmed that discovery in the CERA patent infringement litigation is expected to close by April 30, 2007. However, the trial date has been stretched to sometime in September 2007. Shares of the Thousand Oaks, Calif.-based biotechnology company were up $1.57, or 2.14%, at $74.94. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.